Could a common steroid make AML treatment easier to tolerate?
NCT ID NCT07014462
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether adding the steroid dexamethasone to standard low-intensity chemotherapy is safe and tolerable for adults newly diagnosed with acute myeloid leukemia (AML) who cannot have intensive chemo. About 20 participants will receive the combination over six cycles, with close monitoring for side effects and quality of life. The goal is to see if this approach can reduce treatment-related toxicity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dexamethasone plus venetoclax-based low-intensity therapy (azacitidine, decitabine, or low-dose cytarabine)
- What this could lead to
- If it works, this could point toward a more tolerable treatment option for AML patients who cannot handle intensive chemotherapy.
- What could go wrong
- This is a very early phase 1 trial with only 20 participants, so it is primarily checking safety, not effectiveness. The added dexamethasone may cause side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill tackle Tough-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can a triple-drug combination tame AML without intensive chemo?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- New Triple-Drug strategy aims to boost remission in Hard-to-Treat leukemia
- New drug cocktail aims to boost remission in tough AML cases